claim: single-dose intranasal administration of adcovid elicits systemic and mucosal immunity against sars-cov-2 in humans
evidence_1: therefore, adcovid, which promotes concomitant systemic and local mucosal immunity, represents a promising covid-19 vaccine candidate.